New Escherichia coli (E.coli) strains completely sequenced for high yield bioproduction without the use of antibiotics
2011 BIO International Convention#4822
WASHINGTON--(BUSINESS WIRE)--Delphi Genetics SA ("Delphi") announced today at the BIO convention the launching of StabyExpress strains with a completely sequenced genome. These strains contain different mutations including the genetic locus to use StabyExpress allowing the industrial scale production of high yield recombinant proteins without using antibiotics. Working with these completely sequenced strains allows for the first time the production of biopharmaceutical molecules in a completely characterized genetically production microbial host without using antibiotic resistance genes.
Philippe Gabant PhD, Delphi Genetics Founder and Business Development Director, explained: "Thanks to this new generation of strains with a complete sequenced genome we offer partners for the first time completely genetically characterized strains to perform bioproduction with the StabyExpress technology. The complete genetic characterisation of the host used in bioproduction is a demand of the Regulatory Authorities (FDA, EMEA). The genomes of our new strains are completely sequenced, they are thus in line with the highest genetic standards in terms of characterization and traceability. These strains will allow our partners to produce high yields of their recombinant biopharmaceutical compounds without risk of antibiotic traces in the final products".
In June 2009, Delphi Genetics announced a non-exclusive licensing agreement with Sanofi-Pasteur, the human vaccines division of Sanofi-Aventis and in 2010 another agreement with GSK. These agreements allow Sanofi-Pasteur and GSK to implement the StabyExpress technology for recombinant proteins productions, therefore being able to produce efficiently without the use of antibiotics.
About StabyExpress
StabyExpress technology can be applied to any industrial protein production process that involves bacterial fermentation. Biopharmaceutical production represents a booming market and its share of the overall medication market today is estimated at 15%. Moreover, the technology is consistent with FDA and EMEA recommendations regarding to the elimination of Antibiotic Resistance Genes in protein production processes for both human and veterinary uses. It has been shown that, at industrial scales, the StabyExpress technology very significantly increases the yield of recombinant protein production. Currently, Antibiotic Resistance Genes are used as selection markers for the design of the majority of the genetic systems enabling protein production. Delphi Genetics has announced non-exclusive licensing agreements with Sanofi-Pasteur in 2009 and GSK in 2010.
About Delphi Genetics SA
Founded in late 2001, Delphi Genetics develops more effective products and technologies for genetic engineering and for protein expression in bacteria by using its unique expertise in the field of plasmid stabilisation systems. Delphi Genetics' patented StabyExpress technology increases recombinant protein production output without the use of antibiotics, which is the traditional approach. For further information, please visit our website:
Contacts
Delphi Genetics SA
delphigenetics@delphigenetics.com
Tel: +32 71 25 10 00